Dynamic recrystallization behavior of a biomedical Ti-13Nb-13Zr alloy.
Hyderābād, India. In J Mech Behav Biomed Mater, Jan 2016
UNASSIGNED: The dynamic recrystallization (DRX) behavior of a biomedical titanium Ti-13Nb-13Zr alloy has been investigated using the high temperature compression tests under wide range of strain rates (0.001-1/s) and temperatures 900-1050°C.
ARID1B-mediated disorders: Mutations and possible mechanisms.
Melbourne, Australia. In Intractable Rare Dis Res, Feb 2015
Mutations in the gene encoding AT-rich interactive domain-containing protein 1B (ARID1B) were recently associated with multiple syndromes characterized by developmental delay and intellectual disability, in addition to nonsyndromic intellectual disability.
The ARID1B phenotype: what we have learned so far.
In Am J Med Genet C Semin Med Genet, 2014
Evidence is now accumulating from a number of sequencing studies that ARID1B not only appears to be one of the most frequently mutated intellectual disability (ID) genes, but that the range of phenotypes caused by ARID1B mutations seems to be extremely wide.
ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Boston, United States. In Nat Med, 2014
Here, using a broad screening approach, we identify ARID1B, an ARID1A homolog whose gene product is mutually exclusive with ARID1A in SWI/SNF complexes, as the number 1 gene preferentially required for the survival of ARID1A-mutant cancer cell lines.
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Villingen-Schwenningen, Germany. In Oncologist, 2012
For patients with advanced indolent non-Hodgkin's lymphoma (NHL) or elderly patients with mantle cell lymphoma (MCL), the recently reported results of the German StiL NHL-1 2003 and the international BRIGHT phase III trials showed that, as first-line treatment, the combination of bendamustine and rituximab is at least as effective as rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone or rituximab/cyclophosphamide/vincristine/prednisone, possibly with a better therapeutic index.